基本情報
- CAS
80214-83-1- 標準SMILES
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O- InChIKey
RXZBMPWDPOLZGW-XMRMVWPWSA-N- 分子式
- C41H76N2O15
- 平均分子量
- 837 g/mol
- 単同位体質量
- 836.52456972
概要
Roxithromycin is semisynthetic derivative of erythromycin A. It has a role as an antibacterial drug. It is a macrolide, an erythromycin derivative and a semisynthetic derivative. It is functionally related to an erythromycin A.
名称と識別子
- 優先名称
- Roxithromycin
- IUPAC
- (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
- 現地名
- ロキシスロマイシン
- 英語名
- Roxithromycin
- 分子式
- C41H76N2O15
- 分子量
- 837.05
名称と別名
roxithromycinRulide80214-83-1RulidRU 28965RU 965InfectoroxitRU-965Roxi-paed 1A PharmaRoxitromycinRoxitromycineDTXSID8041117
名称をさらに表示
ロキシメルク9-デオキソ-9-[(2-メトキシエトキシ)メトキシイミノ]エリスロマイシンブリリドフォリリンルリッドルリドロシトロールオーロライド9-デオキソ-9-[[[(2-メトキシエトキシ)メチル]オキシ]イミノ]エリトロマイシンロキスリッドロキシトロマイシンオベラールロキシマインスルリドクララミドロキシトロマイシンAアソラールラドリッドエリスロマイシン9-[O-[(2-メトキシエトキシ)メチル]オキシム]ロトラミンRoxidRoxithromycin (Roxl-150)Roxithromycin Solution, 100ppmBrilidOveralSurlidAssoral
物性
構造計算による物性
- XLogP
- 3.1
- 極性表面積
- 217 Ų
- 水素結合供与体数
- 5
- 水素結合受容体数
- 17
- 回転可能結合数
- 13
- 重原子数
- 58
- 形式電荷
- 0
- 複雑度
- 1,310
実験および物理化学的性質
Drugs
Pharmaceuticals -> Antibiotics
Pharmaceuticals -> Antibiotics
Pharmaceuticals -> Listed in ZINC15
LogP3.46
Human DrugsBreast Feeding; Lactation; Anti-Bacterial Agents; Anti-Infective Agents; Macrolides
Dissociation Constants9.27
Collision Cross Section285.66 Ų [M+Na]+
物理化学的性質
- 融点
- 111 · 111-118C
- 沸点
- 864.7 · 864.7±75.0 °C(Predicted)
- 比旋光度
- 25 · D25 -77.5 ±2° (c = 0.45 in chloroform)
- 比重(密度)
- 1.25 · 1.25±0.1 g/cm3(Predicted)
- 闪点
- 110 ° · >110°(230°F)
- 貯蔵温度
- 2 · Sealed in dry,2-8°C
- 溶解性
- 10 mg/mL · クロロホルム：可溶10mg/mL
- 酸解離定数(Pka)
- 9.27 · pKa 9.27±0.01(H2O t = 25.0 I = 0.15 (KCl)) (Uncertain)
- 外見
- 粉
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 67 reports by companies from 2 notifications to the ECHA C&L Inventory.
Danger
H302: Harmful if swallowed [Warning Acute toxicity, oral]
危険有害性情報
Regulatory InformationRoxithromycin: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and Categories
Acute Tox. 4 (100%)
Acute toxicity (Oral) - Category 4
毒性情報
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
ROXITHROMYCIN
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
安全データ
- wgk
- 3
- rtecs
- KF4990000
- hs_code
- 29415000
- risk_code
- 22
- hazard_code
- Xn
- safety_code
- 26-24/25
- 環境リスク評価
- ロキシスロマイシン(80214-83-1)
化学と産業
薬理情報
ATC Code
J - Antiinfectives for systemic use
QJ - Antiinfectives for systemic use
Protein Binding96%, mainly to alpha1-acid glycoproteins
Pharmacodynamics
Roxithromycin has the following antibacterial spectrum <i>in vitro</i>: <i>Streptococcus agalactiae</i>, <i>Streptococcus pneumoniae</i> (Pneumococcus), <i>Neisseria meningitides</i> (Meningococcus), <i>Listeria monocytogenes</i>, <i>Mycoplasma pneumoniae</i>, <i>Chlamydia trachomatis</i>, <i>Ureaplasma urealyticum</i>, <i>Legionella pneumophila</i>, <i>Helicobacter</i> (Campylobacter), <i>Gardnerella vaginalis</i>, <i>Bordetella pertussis</i>, <i>Moraxella catarrhalis</i> (<i>Branhamella Catarrhalis</i>), and <i>Haemophilus ducreyi</i>. Roxithromycin is highly concentrated in polymorphonuclear leukocytes and macrophages, achieving intracellular concentrations greater than those outside the cell. Roxithromycin enhances the adhesive and chemotactic functions of these cells which in the presence of infection produce phagocytosis and bacterial lysis. Roxithromycin also possesses intracellular bactericidal activity.
Mechanism of ActionRoxithromycin prevents bacterial growth by interfering with their protein synthesis. It binds to the 50S subunit of bacterial ribosomes and inhibits the translocation of peptides.
Biological Half-Life12 hours
Metabolism/Metabolites
Hepatic. Roxithromycin is only partially metabolised, more than half the parent compound being excreted unchanged. Three metabolites have been identified in urine and faeces: the major metabolite is descladinose roxithromycin, with N-mono and N-di-demethyl roxithromycin as minor metabolites. The respective percentage of roxithromycin and these three metabolites is similar in urine and faeces.
MeSH Pharmacological ClassificationSubstances that inhibit the growth or reproduction of BACTERIA.
関連反応
1 件
化合物ノート
読み込み中…